Federal Circuit Affirms Validity of Janssen’s Paliperidone Patent Against Mylan Challenge
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Janssen Pharmaceuticals, Inc. v. Mylan NV |
| Case Number | 25-1252 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District Court (District of Columbia) |
| Duration | Dec 2024 – Jul 2025 215 days |
| Outcome | Plaintiff Win – Patent Validity Affirmed |
| Patents at Issue | |
| Accused Products | Mylan’s proposed generic paliperidone ester products |
Case Overview
The Parties
🛡️ Defendant / Challenger
One of the world’s largest generic and specialty pharmaceutical companies, known for challenging branded drug patents to bring lower-cost alternatives to market.
⚖️ Plaintiff / Patent Holder
A subsidiary of Johnson & Johnson, holding a robust portfolio of branded pharmaceutical patents, including those protecting its long-acting injectable antipsychotic portfolio.
The Patent at Issue
This case centered on U.S. Patent No. US9439906B2, which protects a specialized dosing regimen for long-acting injectable paliperidone esters. This technology aims to improve patient compliance in antipsychotic therapy by enabling monthly or less-frequent dosing cycles.
- • US9439906B2 — Dosing regimen for long-acting injectable paliperidone esters
Developing a similar drug or regimen?
Check if your compound or dosing regimen might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit **affirmed** the district court’s determination that Mylan had not proven the challenged claims of US9439906B2 invalid for obviousness. No damages or injunctive relief were at issue, as the core dispute centered on patent validity. The appeal was subsequently dismissed, leaving Janssen’s patent claims intact.
Key Legal Issues & Significance
The obviousness doctrine under 35 U.S.C. § 103 requires a challenger to demonstrate that a person of ordinary skill in the art would have been motivated to combine prior art references to arrive at the claimed invention, with a reasonable expectation of success. Dosing regimen patents present a particularly nuanced battleground, as specific dosing parameters can constitute non-obvious innovations when they produce unexpected clinical results.
The court’s language states: “We have considered Teva’s other arguments and find them unpersuasive. For the foregoing reasons, we affirm the district court’s determination that the challenged claims have not been proven invalid for obviousness and therefore the court’s judgment.”
Editorial Note: The court’s reference to “Teva” in the verdict language — while the named appellant is Mylan — may reflect underlying consolidated proceedings, a Teva-related subsidiary involvement, or a drafting convention in the appellate record. Practitioners should consult the full appellate opinion for complete context.
This ruling reinforces several important doctrinal principles for pharmaceutical patent litigation:
- High burden on challengers: Generic manufacturers bear the burden of proving invalidity by clear and convincing evidence.
- Dosing regimen patents remain defensible: Specific dosing protocols can be patentable innovations.
- Appellate deference: The Federal Circuit defers to district court factual findings on obviousness.
Developing a New Dosing Regimen?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharma
This case highlights critical IP risks in pharmaceutical dosing regimens. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View related patents in this therapeutic area
- See which companies are most active in long-acting injectables
- Understand claim construction patterns for method-of-treatment
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug compound or dosing regimen.
- Input your drug compound description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Dosing regimens for paliperidone esters
Relevant Patents
In antipsychotic therapeutic area
Design-Around Options
Strategic claim differentiation for new regimens
✅ Key Takeaways
For Patent Attorneys & Litigators
Dosing regimen patents (35 U.S.C. § 103) remain viable and enforceable when supported by clinical non-obviousness evidence.
Search related case law →The high burden on generic challengers (clear and convincing evidence) for obviousness at trial is key.
Explore precedents →For R&D Leaders
Dosing regimen innovation is independently patentable — document clinical rationale and unexpected results during development.
Start FTO analysis for my product →When designing around existing pharmaceutical patents, dosing regimen claims deserve the same FTO scrutiny as compound and formulation claims.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.